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Anaphylaxis, the most serious and life-threatening allergic reaction, produces the 
release of inflammatory mediators by mast cells and basophils. Regulator of calcineurin 
1 (Rcan1) is a negative regulator of mast-cell degranulation. The action of mediators 
leads to vasodilation and an increase in vascular permeability, causing great loss of 
intravascular volume in a short time. Nevertheless, the molecular basis remains unex-
plored on the vascular level. We investigated Rcan1 expression induced by histamine, 
platelet-activating factor (PAF), and epinephrine in primary human vein (HV)-/artery 
(HA)-derived endothelial cells (ECs) and human dermal microvascular ECs (HMVEC-D). 
Vascular permeability was analyzed in vitro in human ECs with forced Rcan1 expression 
using Transwell migration assays and in vivo using Rcan1 knockout mice. Histamine, but 
neither PAF nor epinephrine, induced Rcan1-4 mRNA and protein expression in primary 
HV-ECs, HA-ECs, and HMVEC-D through histamine receptor 1 (H1R). These effects were 
prevented by pharmacological inhibition of calcineurin with cyclosporine A. Moreover, 
intravenous histamine administration increased Rcan1 expression in lung tissues of 
mice undergoing experimental anaphylaxis. Functional in vitro assays showed that over-
expression of Rcan1 promotes barrier integrity, suggesting a role played by this molecule 
in vascular permeability. Consistent with these findings, in vivo models of subcutaneous 
and intravenous histamine-mediated fluid extravasation showed increased response in 
skin, aorta, and lungs of Rcan1-deficient mice compared with wild-type animals. These 
findings reveal that endothelial Rcan1 is synthesized in response to histamine through a 
calcineurin-sensitive pathway and may reduce barrier breakdown, thus contributing to 
the strengthening of the endothelium and resistance to anaphylaxis. These new insights 
underscore its potential role as a regulator of sensitivity to anaphylaxis in humans.
Keywords: anaphylaxis, endothelial cells, vascular permeability, regulator of calcineurin 1, histamine
2Ballesteros-Martinez et al. Rcan1 Promotes Endothelial Barrier Function
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1323
inTrODUcTiOn
Anaphylaxis is a potentially lethal, rapid-onset allergic reaction, 
and is known to be the most aggressive manifestation of allergic 
disorders (1). Anaphylactic reactions trigger a broad range of 
symptoms affecting different organs and bodily systems. The 
severe alterations described in human anaphylaxis involve the 
cardiovascular system and include loss of peripheral vascular 
resistance (vasodilation) and exacerbated vascular extravasation. 
These physiological processes are associated with low blood 
pressure, reduced venous return, and decreased cardiac output. 
Furthermore, bronchoconstriction and pulmonary/coronary-
artery vasoconstriction commonly occur in the thoracic cavity, 
which contributes to widespread circulatory collapse (2–4). The 
clinical features of anaphylaxis have been well-described and 
classified, though investigations into its molecular signaling 
dynamics remain scarce in humans. To date, this hypersensitivity 
event has been considered a disorder of the immune system. 
However, immunological mechanisms do not fully explain the 
versatility of the events that take place during a reaction (5). In 
order to obtain a better understanding of anaphylaxis, we searched 
for new strategies, including the study of vascular mechanisms.
Molecules released mainly by active mast cells and basophiles 
interact with the vascular endothelium and the smooth muscle 
layers, destabilizing the endothelial barrier and modifying essen-
tial vascular contractile functions (tone) in vessels and airways (6). 
Tryptase, histamine, and platelet-activating factor (PAF) are only 
two such relevant biochemical mediators found in the serum of 
anaphylaxis patients (7). In cells, histamine binds to four types of 
receptors coupled to G proteins (H1-4R), and these receptors are 
widely distributed across tissues and leads to signaling through 
numerous molecular pathways. Type-1 and type-2 histamine 
receptors (H1R and H2R) have been widely investigated due to the 
fact that they mediate the intracellular signaling associated with 
second messengers such as Ca2+ and cAMP, which regulate vas-
cular permeability, vasodilation, and bronchoconstriction (8, 9). 
In order to control these homeostatic disorders, the first-line treat-
ment for anaphylaxis is intramuscular injection of epinephrine, 
which acts via α- and β-adrenergic receptors, triggering intracel-
lular mechanisms in cardiac and smooth vascular cells (10). Their 
potent vasoconstrictor actions combined with fluid therapy are 
effective when administered promptly (11). Moreover, the second 
messenger cAMP is mediated by activation of β-adrenergic recep-
tor signaling and contributes to the maintenance of endothelial 
barrier properties under baseline conditions (12).
There is growing interest in understanding the vascular 
permeability and vasodilation that occur during anaphylaxis. 
Different endothelial molecular pathways have been described as 
key targets for anaphylaxis due to their implication in the disrup-
tion of endothelial integrity or vascular tone modulation (13, 14). 
In humans, changes in vascular permeability during anaphylaxis 
may lead to a transfer of 50% of the intravascular fluid into the 
interstitial space within 10 min (3). At the molecular and cellular 
level, it is well known that histamine induces rapid and transient 
processes, which disrupt the endothelial barrier, thereby allow-
ing the leakage of fluids, mainly in venules (15). Furthermore, 
endothelial cells (ECs) participate in physiological processes 
that regulate not only the capillary component but also peri-
pheral vascular resistance and homeostasis. This fact is a focus of 
research in vascular permeability modulation (16), and vascular 
wall components are also essential in regulating leakage and 
peripheral vascular resistance in anaphylaxis. Mechanistically, a 
cellular counterbalance between contractile and adhesive forces 
must exist to maintain the stability between cells and prevent the 
rupture of the endothelial barrier (17). It has been reported that 
ECs contribute to the widespread effects observed in anaphylaxis 
through synthesis and the release of substances, including nitric 
oxide (NO) and mediators generated from the arachidonic acid 
cascades (18). However, mast cells are the main cellular source 
recognized to date, and are major releasers of prostaglandins and 
leukotrienes eliciting anaphylaxis reactions (19, 20).
Histamine binding to H1 receptors activates PLCβ and elevates 
intracellular Ca2+, both of which determine the signaling pathways 
which regulate inflammatory processes. Via Ca2+-dependent mech-
anisms, changes take place in cytoskeleton proteins or junction 
structures that determine cellular permeability and contractility 
(21). One of the most sensitive downstream effectors of Ca2+ is 
the ubiquitously expressed serine/threonine protein phosphatase 
calcineurin (22). Activation of calcineurin contributes to immune 
response signaling by members of the nuclear factor of activated 
T-cells (NFAT) family (23). Calcineurin activity can be inhibited 
by the immunosuppressant cyclosporine A (CsA) which forms 
a complex with cyclophilin A to bind and competitively inhibit 
calcineurin phosphatase activity (24). Endogenous regulation of 
calcineurin is mediated by members of the regulator of calcineu-
rin (Rcan) family, and Rcan1 is the only such molecule regulated 
by Ca2+/calcineurin (25). The RCAN1 gene contains seven exons 
that can generate several transcripts resulting from differential 
promoter use and first exon choice. The two major transcriptional 
products for Rcan1 are isoforms, including exons 1 + 5–7 (Rcan1-
1) and isoform 4 (Rcan1-4) with exons 4 + 5–7, which produce 
proteins with 252 and 197 amino acids, respectively (26, 27).
Divergent functions have been reported for both Rcan1-1 
and Rcan1-4. While different inducers of Ca2+ selectively 
upregulate Rcan1-4, few stimuli have been described as modu-
lators of Rcan1-1 expression. A role for apoptosis is attributed 
to Rcan1-1 in response to glucocorticoids, and relevant studies 
have linked Rcan1-1 to Huntington disease (28, 29). Rcan1-4 
is upregulated by increases in Ca2 or in response to a variety 
of signals, including cytokines, hormones, hydrogen peroxide, 
and stress (30). Functionally, it has been widely described as an 
anti-inflammatory, anti-angiogenic agent and modulator of car-
diovascular pathologies (31, 32). Due to its influence in regulating 
calcineurin activity, Rcan1 is involved in a broad range of cellular 
systems and biological processes. Extensive investigations have 
provided insights into EC signaling, describing Rcan1 as a poten-
tial therapeutic target in vascular inflammation (33). VEGF and 
thrombin have been reported to be the major inducers of Rcan1 
in ECs, while angiotensin II induces Rcan1 expression in vascular 
smooth muscle cells (34–36).
Given the crucial role exerted by mediators on the vascular wall 
in anaphylaxis, we assessed the impact of anaphylaxis on Rcan1 
expression in human ECs, as well as its functional involvement 
in vascular permeability and cell dilation. This study evaluates 
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Rcan1 expression in human ECs in response to mediators of 
anaphylaxis and, more specifically, the involvement of histamine 
receptors involved in Rcan1 expression. Moreover, we studied the 
permeability effects of Rcan1 causing either endothelial barrier 
rupture or strengthening in response to mediators of anaphylaxis 
and also analyzed the plausible endothelial mechanisms exerting 
these functions.
MaTerials anD MeThODs
In Vitro human cell cultures
Human dermal microvascular ECs (HMVEC-D) were acquired 
from Lonza. Human vascular endothelial vein and artery cells 
were isolated from the macroscopically healthy part of intact 
saphenous veins harvested from patients undergoing bypass 
surgery/high ligation of varicose veins. The study was approved 
by the research ethics committees of the Gentofte and FJD 
hospitals, and written informed consent was obtained from all 
patients. Briefly, after removal of the connective tissue, the vein 
was opened longitudinally and the endothelium was isolated 
by digestion with 0.1% type I collagenase (Gibco) in PBS for 
30 min at 37°C. Similarly, artery specimens were incubated with 
the digestion buffer O.N at 37°C. Reactions were stopped and 
cells were collected by centrifugation and grown in DMEMF12 
media supplemented with 10  U/ml heparin, 30  g/ml ECGF, 
100  U/ml penicillin, 100  g/ml streptomycin, and 15% (v/v) 
heat-inactivated fetal bovine serum. Cells were seeded in a plate 
previously coated with 0.5% sterile gelatin and maintained in a 
humidified atmosphere of 5% CO2 in air at 37°C. After 5–7 days 
of incubation, human vein or artery ECs (abbreviated herein as 
HV-EC/HA-ECs) were selected with human CD31 antibody. 
Next, the secondary antibody associated with magnetic beads 
(Dynabeads® anti-mouse IgG from CELLection ™ Pan Mouse 
IgG Kit) was incubated for 30 min at 4°C with constant shaking. 
ECs were seeded on plates previously treated with 0.5% gelatin. 
Once in confluence, primary cell cultures were FBS 0.5% starved 
for 18 h before the experiments were performed. All experiments 
were performed during passages 3–7. A similar protocol was 
applied to the artery specimens.
reagents
Histamine, PAF, epinephrine, and the histamine receptor antago-
nists diphenhydramine hydrochloride (H1RB) and famotidine 
(H2RB) were obtained from Sigma.
Protein extraction and immunoblot 
analysis
Endothelial cells were lysed with buffer containing Tris, NaCl, 
EDTA, EGTA, Triton X-100, NP40, protease inhibitors, PMSF, 
and DTT. Cellular lysates were shaken for 15 min and centrifuged 
at 12,000 rpm at 4°C. After stimulation with reagents or sera, ECs 
were washed with ice-cold PBS and protein extracts obtained as 
previously described (36). Rabbit polyclonal anti-Rcan1 primary 
antibody was used at a ratio of 1/1,000 (Sigma). Analysis of images 
was carried out using the ImageJ program. Protein extracts from 
animal tissues were previously disaggregated and processed in 
similar fashion.
mrna extraction, rT, and real-time Pcr 
analysis
RNA extraction was performed using Tri Reagent (Molecular 
Research Center). Two micrograms of total RNA were reverse trans-
cribed following the instructions for the high-capacity cDNA RT 
(Thermo Fisher) protocol, and samples were stored at −70°C (36). The 
following TaqMan FAM/MGB probes were purchased from Applied 
Biosystems: human Rcan1 (Hs01120954_m1), human Rcan1.1 
(Hs01120956_m1), human PTGS2 (Hs00153133_m1), human 
MYLK (Hs00364926_m1), human NOS3 (Hs01574659_m1), 
human ROCK1 (Hs01127699_m1), and human CAMK2B 
(Hs00365799_m1). Human Rcan1.4 was purchased customized 
according to primer forward: GCAAACAGTGATATCTTCAG 
CGAAA, primer reverse: GTGATGTCCTTGTCATACGTCCTAA, 
and the labeled CAGGGCCAAATTT (5 NFQ). Reactions were 
incubated in the presence of AmpliTaq Gold DNA polymerase 
(Applied Biosystems) for 2  min at 50°C followed by 10  min at 
95°C. Reactions were then run over 40 cycles of 95°C for 15 s and 
60°C for 1 min. Human beta actin VIC/MGB or 18s VIC/MGB 
rRNA transcripts were used as an internal control, which were 
amplified in the same tube to normalize for variation in input 
RNA. The amount of target mRNA in the samples was estimated 
by the 2CT relative quantification method. Ratios were calculated 
between the amounts of mRNA from stimulated and/or transfected 
vs nonstimulated control ECs.
In Vitro Vascular Permeability assays
Endothelial barrier integrity was evaluated by using Transwell 
24-well cell culture inserts (TW) including a membrane pore size 
of 0.4 µm (Corning). ECs were seeded at a density of 105 cells/
well in TWs previously coated with 0.5% gelatin diluted in sterile 
water and grown in DMEMF12 media supplemented as described 
above. After several days, EC monolayers were observed and 
starved for 18 h before the experiments were performed. Stimulus 
together with a final concentration of 1 mg/ml of FITC-Dextran 
(Sigma) was added to the upper chamber. Vascular endothelial-
permeability measurements were determined by measuring 
fluorescence of the recipient at 5–30 min and 2 h. All samples 
were evaluated at least in duplicate.
lentiviral Production and infection
Lentiviruses expressing Rcan1-1-IRES-GFP, Rcan1-4-IRES-GFP, 
and IRES-GFP were obtained by transient calcium phosphate 
transfection of HEK-293. The supernatant containing the 
lentiviral particles was collected 48  h after removal of the cal-
cium phosphate precipitate, filtered through a 45-µM PVDF 
membrane (Steriflip; Millipore), and ultracentrifuged for 2 h at 
26,000 rpm at 4°C (Ultraclear Tubes, SW28 rotor, and Optima 
l–100 XP Ultracentrifuge; Beckman Coulter). Viruses were 
resuspended, titrated, and infection efficiency (GFP-expressing 
cells) was monitored by flow cytometry (36). Lentiviral infection 
was performed in subconfluent primary cultures of ECs with a 1:1 
mix including Rcan1-IRES-GFP (Rcan1-1-IRES-GFP + Rcan1-
4-IRES-GFP) or IRES-GFP. Cells were exposed to the lentiviruses 
in the presence of 10% FBS during 5 h (37). After 4 days, cells 
were starved of FBS (0.5%) during for 18 h and the experiments 
of interest were performed.
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animal experimental Designs
Animal procedures were carried out in accordance with the 
European Union guidelines for the care and experimental use of 
animals. Protocols with reference PROEX: 391/15 received prior 
approval from the IIS-FJD Ethics Committee and the competent 
authorities in the region of Madrid.
Two-month-old C57BL/6J mice were intravenously (i.v.) 
injected with Evans blue (0.04 µg/g in NaCl) followed by subcu-
taneous (s.c.) injection with histamine and PAF at 5–50 ng/ml for 
10 min. To evaluate systemic vascular permeability, histamine at 
10 mg/kg or PAF 2 µg/g were i.v. injected together with Evans blue 
dye. Once i.v. administrated, mice were sacrificed after 15 min, 
and most PAF animals died spontaneously. The skin pieces, aor-
tas, lungs, and hearts of these animals were incubated in 500 µl 
of formamide at 55°C for 48 h, and the Evans blue content was 
determined by absorption at 595  nm. To test passive systemic 
anaphylaxis (PSA) using an experimental in  vivo model, mice 
were i.v. injected with 20  µg of anti-DNP IgE. After 24  h, the 
mice were challenged with an i.v. injection of 1 mg DNP-HSA 
(human serum albumin) for the development of anaphylaxis. 
To test for active systemic anaphylaxis (ASA), we used the 
classical model, sensitizing mice with i.p injection of 1 mg BSA 
and 300 ng pertussis toxins as adjuvant in normal saline. After 
14 days, the mice were challenged with i.v. injection of 2 mg BSA 
(38). Following administration of s.c. and i.v. histamine, PSA and 
ASA mice were sacrificed 30 min after the challenge by cervical 
dislocation, and blood sampling and biopsies (organ collection) 
were collected for molecular analysis. All studies were repeated at 
least once to assure reproducibility. Rcan1-deficient (−/−) mice 
were generated as previously described (39). All mice were geno-
typed by PCR of tail samples using the following primers: Rcan1, 
5′-GGTGGTCCACGTGTGTGAGA-3′, 5′-ACGTGAACAAAG 
GCTGGTCCT-3′, and 5′-ATTCGCAGCGCATCGCCTTCTAT 
CGCC-3′. Control littermates were used in all experiments.
statistical analysis
All values are expressed as the mean ±  SEM. Differences were 
evaluated with GraphPad Prism 7.3 program using one-way 
ANOVA analysis followed by Bonferroni’s post hoc test (experi-
ments ≥3 groups) or Student’s t-test (experiments with two 
groups). Statistical significance was set at p < 0.05.
resUlTs
histamine increases rcan1-4  
expression in hV-ec
Previous studies have demonstrated the stimulation of Rcan1-4 
protein induced by agents that cause the mobilization of Ca2+  
(33, 34, 36). We observed that histamine stimulation induces a 
specific increase in Rcan1-4 but not Rcan1-1 protein after a short 
period (30 min of stimulation); the increase was considerably greater 
after 60 min of exposure in HV-ECs (Figures 1A,B). Parallel to 
these results, Rcan1-4 mRNA expression also increased during the 
same time frame in response to histamine (Figure 1C). Moreover, 
as histamine is not the sole mediator recognized for anaphylaxis, 
we addressed the effect of PAF on HV-ECs. Over the last decade, 
evidence based primarily on animal models has indicated the 
existence of an anaphylaxis reaction mediated by IgG- FcγRIII 
(5, 40), and PAF has been recognized as essential in those non-IgE-
mediated reactions (41). In our studies, PAF did not modify Rcan1-4 
protein expression in HV-ECs (Figures 1A,B). Additionally, since 
epinephrine/adrenaline is the first-line treatment in anaphylaxis 
(1, 42), we set out to determine whether epinephrine could modu-
late Rcan1-4 expression in ECs. Incubation of epinephrine from 
15 min to 1 h did not modify Rcan1-4 protein expression; however, 
histamine and epinephrine coincubation increased the expression 
of the Rcan1-4 protein in HV-ECs (Figures  1D,E). As with the 
protein findings, Rcan1 mRNA expression increased in response 
to histamine and epinephrine (Figure 1F). In all cases, the Rcan1-1 
protein and mRNA isoform was unchanged in its expression.
histamine increases rcan1-4 expression 
in ha-ec, hMVec-D, and lungs of 
experimental anaphylaxis
The cellular heterogeneity of the whole endothelial compart-
ment has been recognized for some time. Both intracellular 
mechanisms and functional abilities may be different between 
the micro-, artery, or vein ECs (43, 44). For this reason, we next 
checked Rcan1-4 modulation by histamine and epinephrine in 
other endothelial vascular microenvironments. By using primary 
artery-derived ECs (HA-EC), our results showed that the contact 
with histamine induced a marked increase in Rcan1-4 protein 
expression after 30 min and 1 h (Figures 2A,B), which was corre-
lated with elevated levels of Rcan1-4 mRNA expression (data not 
shown). As we previously observed in HV-ECs, epinephrine had 
no effect on Rcan1-4 expression when incubated alone; however, 
coincubation with histamine induced a high Rcan1-4 increase in 
HA-ECs. Additionally, experiments addressing Rcan1 expression 
in human dermal microvascular ECs (HMVEC-D) showed simi-
larly increased levels of Rcan1-4 protein and mRNA expression 
in response to histamine. Contrary to this, no effect was observed 
upon epinephrine stimulation within the studied time frame in 
HMVEC-D (Figures 2C,D). These results suggest that histamine 
modulates Rcan1-4 expression in ECs of large vessels regardless 
of whether they are veins, arteries, or the microvasculature.
The molecular and physiological differences found between 
studies in animals and studies in humans have sparked debate 
in anaphylaxis as well as other fields of research (5). Using three 
experimental designs simulating different degrees of allergic sen-
sitivity, we looked for Rcan1 expression in target organs in mice 
undergoing anaphylaxis. Experimental passive anaphylaxis (PSA) 
is based on systemic IgE anti-DNP sensitization over 24 h, while 
ASA was induced by BSA followed by challenge 14  days later. 
Analysis of Rcan1 expression in lung extracts of mice treated with 
histamine for 30 min or undergoing PSA or ASA showed increased 
Rcan1-4 levels compared to lungs of control mice (Figures 2E,F).
rcan1-4 Protein expression is induced by 
histamine via its h1 receptor and a 
calcineurin-Dependent Mechanism
Studies were performed to evaluate the relevant receptors (H1R/
H2R) involved in histamine-induced Rcan1-4 expression. 
FigUre 1 | Histamine increases Rcan1-4 protein and mRNA expression in human vein (HV)-endothelial cells (ECs). HV-ECs were treated with epinephrine (1 µM), 
histamine (1 µM), or platelet-activating factor (PAF) (0.1 µM) at indicated times. (a) Representative immunoblots show Rcan1-1 (35 kDa) and Rcan1-4 (28 kDa) 
expression in stimulated extracts. (B) Quantifications were normalized to β-actin and expressed as times of relative change to nonstimulated (basal) cells. Data 
represent means ± SEM of three and four experiments performed at 30 and 60 min, respectively. One-way ANOVA followed Bonferroni’s multiple comparisons test 
was performed for each time studied [*P = 0.0375 vs basal (30 min), ****P < 0.0001 (60 min)]. (c) qPCR analysis of Rcan1-1 and Rcan1-4 mRNA with indicated 
stimulus and times normalized to the endogenous 18s gene. Data represent means ± SEM of four experiments performed at 15, 30, and 60 min. One-way ANOVA 
followed Bonferroni’s multiple comparisons test was performed (**P = 0.0052 vs basal). (D–e) HV-ECs were treated with epinephrine, histamine, and histamine in 
the presence of epinephrine at indicated times. (D) Representative immunoblots. (e) Quantifications were normalized to β-actin and expressed as times of relative 
change to nonstimulated (basal) cells. Data represent means ± SEM of five experiments performed at 15, 30, and 60 min. One-way ANOVA followed Bonferroni’s 
multiple comparisons test was performed (****P < 0.0001, ***P = 0.0009 vs basal). (F) qPCR analysis of total Rcan1 mRNA with indicated stimulus and times 
normalized to endogenous gene expression. Data represent means ± SEM of six experiments performed at 15, 30, and 60 min. One-way ANOVA followed 
Bonferroni’s multiple comparisons test was performed (****P < 0.0001, **P = 0.0019).
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Prior to stimulation with histamine, HV-ECs were incubated 
with increasing concentrations of diphenhydramine hydro-
chloride (type 1 receptor antagonist), determining the optimal 
concentration of use at 10−5  M. Cellular pre-incubation with 
diphenhydramine hydrochloride completely blocked Rcan1-4 
expression induced by histamine in HV-ECs (Figures  3A–C). 
In contrast, no inhibitory effect mediated by famotidine (type 2 
receptor antagonist) was observed; indeed, an additional increase 
in Rcan1-4 expression induced by histamine stimulation was 
noted when the receptor type 2 was blocked (Figures  3A–D). 
Additionally, coincubation with antagonists for both receptors 
(diphenhydramine hydrochloride plus famotidine) abolished 
Rcan1-4 expression induced by histamine in HV-EC and HA-ECs 
(Figures 3C,D).
Next, we investigated the potential role of calcineurin in 
mediating Rcan1-4 expression induced by histamine. Cellular 
pre-incubation with CsA completely blocked Rcan1-4 expression 
induced by histamine in HV-ECs and HMVEC-D (Figures 3E,F). 
Similar to the protein findings, Rcan1-4 mRNA expression was 
significantly diminished in the presence of CsA (Figure  3G). 
FigUre 2 | Rcan1-4 expression is modulated in response to histamine in other cellular microenvironments—HA-ECs, HMVEC-D, and lungs from experimental 
anaphylaxis. HA-ECs and HMVEC-D were treated with epinephrine (1 µM) and/or histamine (1 µM). (a) Representative immunoblots show Rcan1-1 (35 kDa)  
and Rcan1-4 (28 kDa) expression in stimulated HA-ECs for 15, 30, and 60 min. (B) Quantifications were normalized to β-actin and expressed as times of relative  
change to nonstimulated (basal) cells. (c) Representative immunoblots show Rcan1-1 (35 kDa) and Rcan1-4 (28 kDa) expression in HMVEC-D for 60 min.  
(D) Quantifications were normalized to β-actin and expressed as times of relative change to nonstimulated (basal) cells. Data represent means ± SEM of five 
experiments performed per cellular type at 60 min. One-way ANOVA followed Bonferroni’s multiple comparisons test was performed for each cellular type  
studied (HA-ECs; *P = 0.0115, vs basal, HMVEC-D; *P = 0.0135, vs basal). (e) Immunoblots include representative lung extracts from wild-type control mice 
C57BL6, injected i.v. with Hist, active systemic anaphylaxis (ASA), or passive systemic anaphylaxis (PSA). (F) Quantification was normalized to GAPDH and 
expressed as times of relative change to control mice. Data represent means ± SEM of five animals per group. Unpaired t-tests were performed vs control  
(Rcan1-1 *P = 0.0462; Rcan1-4 *P < 0.02).
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In addition, an increase in calcineurin phosphatase activity 
is observed in response to histamine in HMVEC-D (data not 
shown).
human rcan1 induces Marked Prevention 
in Vascular Permeability, strengthening 
the endothelial contact
In vitro ECs adhere to coated surfaces, making up the endothe-
lial monolayer. To evaluate vascular permeability in  vitro, we 
employed available assay systems (Transwell, TW) based on 
measurements of extravasations of fluids through an endothelial 
monolayer. These cells supported on permeable membranes are 
inserted in individual containers that allow the transport of mol-
ecules through them (Figure 4A). First, it was verified that the 
system allows a measurable increase of FITC-Dextran over time. 
EC monolayer blocks the passage of the dye in resting conditions 
(and only endothelial permeability is increased throughout the 
course of the experiment). As expected, short incubations (min-
utes) with the vasoactive mediators histamine and PAF induced a 
rapid increase in vascular permeability on HMVEC-D, which was 
not observed by incubation with epinephrine (12). The response 
duration and sensitivity induced by histamine may vary depend-
ing on ECs (45). After 15–30 min, we observed a clear tendency 
to block the passage of molecules across the endothelial barrier 
both in the presence of histamine and epinephrine, indicating a 
transient effect of histamine on vascular permeability followed 
by cell dilation. At this time, only PAF continued destabilizing 
the endothelial barrier (Figure 4B). Following this, we checked 
the histamine-induced barrier effects in ECs of big vessels. Our 
studies did not show modification in barrier properties after short 
periods of stimulation with histamine in HV-ECs or HA-ECs. 
However, a clear cell-dilating effect induced by histamine is 
FigUre 3 | Histamine induces Rcan1-4 protein expression via its H1 receptor and CsA sensitive manner. Cells were preincubated with diphenhydramine 
hydrochloride (H1 receptor antagonist) and famotidine (H2 receptor antagonist) for 30 min at indicated concentrations previously to histamine 1 µM stimulation.  
(a) Representative immunoblots show Rcan1-1 (35 kDa) and Rcan1-4 (28 kDa) expression in stimulated human vein (HV)-endothelial cells (ECs). (B) Quantifications 
were normalized to β-actin and expressed as times of relative change to nonstimulated (basal) cells. Data represent means ± SEM of five experiments performed. 
One-way ANOVA followed Bonferroni’s multiple comparisons test was performed (*P < 0.05). (c,D) Representative immunoblots show Rcan1-1 (35 kDa) and 
Rcan1-4 (28 kDa) expression in stimulated HV-ECs and HA-ECs preincubated with diphenhydramine hydrochloride, famotidine and a combination of both at a 
concentration of 10−5 M. (e,F) Rcan1 immunoblot in extracts from HV-ECs stimulated with histamine 1 µM at indicated times after pretreatment as indicated 
(30 min) with 200 ng/ml CsA (cyclosporine A). Representative immunoblots show Rcan1-1 (35 kDa) and Rcan1-4 (28 kDa) expression in stimulated HV-ECs.  
(F) Quantifications were normalized to β-actin and expressed as times of relative change to non-stimulated (basal) cells. Data represent means ± SEM of five and  
six experiments, respectively, performed on HV-ECs (black bars) and HMVEC-D (white bars) at 60 min. One-way ANOVA followed Bonferroni’s multiple comparisons 
tests were performed (HV-ECs *P = 0.0232; HMVEC-D **P = 0.0022). (g) qPCR analysis of Rcan1-1 and Rcan1-4 mRNA with indicated stimulus normalized to the 
endogenous 18s gene. Data represent means ± SEM of four experiments performed at 60 min. One-way ANOVA followed Bonferroni’s multiple comparisons test 
was performed (*P = 0.0197 vs basal).
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observed in HV-ECs, and a tendency toward this same dynamic 
was seen in HA-ECs (Figure 4C). In order to determine whether 
Rcan1 has a functional contribution in these processes, we used 
lentiviral constructs aimed at exogenously modifying Rcan1 
expression on ECs. HV-ECs were transduced with Rcan1-
IRES-GFP or the lentiviral control IRES-GFP. The efficiency of 
infection in human cell cultures was analyzed by GFP expression 
using flow cytometry (data not shown), fluorescence microscopy, 
and Western blotting (Figure 4D). Lentiviral infection does not 
modify the effects of histamine on cells, as the Rcan1 pattern 
expression showed the increase of Rcan1-4 protein resembling 
that seen in non-transduced cells for both IRES-GFP and Rcan1-
IRES-GFP HV-ECs (Figures 1–3).
To evaluate the role of Rcan1 in vascular permeability, IRES-
GFP and Rcan1-IRES-GFP HV-ECs were seeded in TW and 
stimulated with or without histamine for 30  min. Data show 
that Rcan1 overexpression prevents basal FITC extravasation 
in HV-ECs, indicating a marked role of Rcan1 in blocking cell 
permeability. In addition, HV-ECs infected with control vector 
and exposed to histamine produced an effect resembling the 
one observed previously in non-transduced cells. However, no 
additional effects of histamine were observed when the cells 
FigUre 4 | Regulator of calcineurin 1 (Rcan1) maintains the endothelial barrier integrity in human vein (HV)-endothelial cells (ECs). (a) Integrity of endothelial 
monolayers was evaluated using TW assays. (B) Quantification of FITC-Dextran molecules extravasated to the TW container and expressed as times of relative 
change to untreated (basal) cells for 5 (left bars), 30, and 120 min (right bars). Data represent means ± SEM of duplicates determined by TW in five independent 
experiments performed on HMVEC-D. One-way ANOVA followed Bonferroni’s multiple comparisons tests were performed for each time studied (*P < 0.05, 
**P < 0.001). (c) Quantifications expressed as times of relative change to untreated HV-ECs or HA-ECs, respectively, for 30 min. Data represent means ± SEM of 
duplicates determined by TW in five independent experiments performed in each genotype. Unpaired t-tests were performed vs basal cells (***P = 0.0003 vs basal 
HV-ECs). (D) The correct infection with lentiviral constructions expressing IRES-GFP or Rcan1-GFP were detected by fluorescence microscopy and analyzed by 
Western blot. The panel shows Rcan1-IRES-GFP extracts modified by infection expressing both exogenously overexpressed isoforms (Rcan1-1 and Rcan1-4).  
(e) Quantification of FITC-dextran molecules extravasated to the TW container and expressed as times of relative change to IRES-GFP cells not treated with 
histamine 1 µM for 30 min. Data represent means ± SEM of duplicates determined by TW in six (IRES-GFP) and seven (Rcan1-IRES-GFP) independent experiments 
performed on HV-ECs. One-way ANOVA followed Bonferroni’s multiple comparisons tests was performed (**P < 0.0057, ##P < 0.0094, &&P < 0.0012 vs IRES-GFP 
control). (F) Quantification of FITC-dextran molecules extravasated to the TW container and expressed as times of relative change to IRES-GFP cells for 5, 30, and 
120 min. Data represent means ± SEM of duplicates determined by TW in three independent experiments performed on HV-ECs. One-way ANOVA followed 
Bonferroni’s multiple comparisons tests was performed (***P = 0.0007, **P = 0.0069 vs IRES-GFP).
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overexpressed Rcan1 endogenously (Figure 4E). To determine 
whether Rcan1 can also affect the earliest phases of extravasa-
tion and its stability over time, time frames of 5 and 120 min 
were used for the measurements (Figure  4F). Our results 
indicate that Rcan1 stabilizes the endothelial barrier during 
short incubation times, though this effect is weakened when 
incubation is longer.
We, therefore, speculated that increased expression of Rcan1 
in ECs could in turn modulate other primordial factors involved 
in anaphylaxis. To test this hypothesis, we analyzed the expres-
sion of some genes involved in vascular homeostasis and barrier 
stability: cyclooxygenase-2 (COX-2), calmodulin-dependent 
protein kinase II-dependent (CaMKII), nitric oxide synthase 3 
(NOS3), MLC-kinase (MLCK), and Rho-kinase 1 (ROCK1) in 
resting and histamine-stimulated IRES-GFP and Rcan1-IRES-
GFP HV-ECs. Resting Rcan1-IRES-GFP HV-ECs showed a 
marked inhibition of COX-2 mRNA, CaMKII mRNA, and NOS3 
expression. However, similar levels of MLCK and ROCK1 were 
observed compared to IRES-GFP HV-ECs (Figure 5). This brief 
screening suggests that consequent generation of newly formed 
proinflammatory phospholipid-endothelial derived COX-2 could 
contribute to vascular contractile processes concomitant to 
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anaphylactic reactions. Additionally, a direct effect on the pro-
duction of the NO is exerted when Rcan1 is overexpressed.
Mouse Rcan1−/− Tissues Present higher 
leakage in response to s.c. and i.v. 
histamine administration
The in  vitro results described above led us to investigate the 
role of Rcan1 in experimental vascular permeability in  vivo. 
We examined the effect exerted by histamine and PAF on vascular 
permeability in Rcan1-deficient vs WT mice. NaCl s.c. injection 
does not modify basal extravasation in WT and Rcan1−/− mice 
(data not shown). However, an increase of leakage was seen in 
response to s.c. injection of histamine in both types of mice, 
and this increase was dose-dependent and significantly higher 
in Rcan1−/− mice (Figures 6A,B). Moreover, histamine adminis-
trated intravenously increased extravasation in aortas and lungs, 
though not in the hearts of Rcan1−/− mice, while no significant 
difference was observed in response to PAF between genotypes 
(Figures 6B,C). As in the in vitro human cells, endothelial Rcan1 
may prevent or recover the loss of endothelial barrier function 
induced by histamine.
DiscUssiOn
The functional heterogeneity between different EC niches and 
their importance in the release of certain physiological factors 
contributing to pathological situations is a topic of high relevance 
in important fields of research (16, 46). Therefore, in anaphylaxis 
affecting a large number of organs, it is plausible that the vascular 
system is a critical participant in the evolution of symptoms and 
one that may condition the progress of reactions. This study 
provides the first evidence that histamine, a relevant mediator 
involved in anaphylactic reactions, modulates Rcan1-4 expres-
sion in different human vascular niches (HV-ECs, HA-ECs, and 
HMVEC-D). Different authors have previously reported that 
factors such as VEGF and thrombin induce Rcan1-4 expression 
in cultured ECs (34, 47). Given the major role of histamine 
when released by immune cells as a mediator of anaphylactic 
reactions, our results extend previous findings, showing that 
histamine upregulates Rcan1-4 expression in several types of 
ECs, whereas Rcan1-1 is not modulated. In agreement with our 
findings, a number of studies performed on this cellular type did 
not observe significant Rcan1-1 variation in response to stimuli 
(34) in spite of its involvement in Huntington disease and mito-
chondrial autophagy (29, 48). Additionally, epinephrine has no 
effect on Rcan1 expression, and although its potent actions as a 
dilator or constrictor through its adrenergic receptors have been 
widely observed, its role in the endothelium has been poorly 
investigated. However, the contributions of epinephrine to the 
maintenance of the endothelial barrier, through its β-adrenergic 
receptors, have been evaluated in ECs (12). Similarly, a sub-
stantial number of studies have demonstrated the role of PAF 
in anaphylaxis. The data shown here do not support a role for 
PAF in modulating Rcan1-4 expression in ECs, at least in our 
experimental conditions. However, given the relevance of PAF, 
more thorough studies focused on human vascular cells would 
be of interest to clarify unexplored aspects that thus far have been 
mostly related to reactions mediated by IgE or IgG antibodies in 
anaphylaxis (5, 41).
The human H1R acts mainly by coupling to Gq/11 proteins; in 
fact, experimental anaphylaxis is prevented in endothelial Gq/11-
deficient mice (38). Through its specific signal, histamine is one 
of the most potent vasoactive substances, inducing relaxation or 
contraction (tissue- and species-dependent) and participating 
in anaphylactic responses, mainly through its H1R and H2R 
receptors (8, 9). The data shown here demonstrate that histamine 
increases Rcan1 expression through the H1R receptor in ECs 
due to a calcineurin-dependent mechanism, as the calcineurin 
inhibitor CsA inhibits its expression.
Anaphylaxis is widely recognized by the presence of increased 
vascular permeability, mediating a shift of intravascular fluid into 
the extravascular space within minutes, which results in hypoten-
sion and hemoconcentration (3). Some studies in human subjects 
have revealed transient impairment of the microvasculature dur-
ing severe acute anaphylaxis (49). Thus, the leakage occurring 
in anaphylaxis requires cellular retraction of ECs as a result of 
increased cell contractile pathways in response to external stimuli 
or agents (15). Subsequently, a biological counterbalance between 
contractile and adhesive forces must exist to maintain the stabil-
ity between cells or allow cells to recover from the rupture of 
the endothelial sheet. Thus, most of the mediators described in 
anaphylaxis elicit vascular EC permeability signaling through 
specific receptors and molecular pathways. However, some sta-
bilizing molecules preserve the rupture of the endothelial barrier 
(as cAMP or sphingosine 1 phosphate). The functional evaluation 
of Rcan1 by using in vitro permeability assays and in vivo extrava-
sation mice models show Rcan1 as a stabilizer of the endothelial 
barrier or as a cellular dilator agent. Our studies demonstrate 
that histamine-induced Rcan1 contributes to the stability of the 
endothelial barrier and also indicate that this mechanism is a 
late-secondary response to prevent the loss of fluids and/or the 
regulation of vascular tone.
Our studies demonstrate that exogenous overexpression of 
Rcan1 downregulates the expression of calcineurin-related genes 
such as COX2, NOS3, and CaMKII. H1R stimulation increases 
NOS3 synthesis through a mechanism that involves CaMKII in 
human vascular ECs (24, 50). NOS3 upregulation and consequent 
NO production is protective under normal conditions, though 
may be deleterious in a model of experimental anaphylaxis (51, 52). 
Our studies correlate the stability of the endothelial barrier with 
a decreased NOS3 expression in Rcan1 overexpressed cells, as 
well as a tendency to prevent the increase of NOS3 induced by 
histamine, suggesting a protective vasodilator role for Rcan1 in 
ECs. Interestingly, CaMKII has been reported as a suppressor of 
intracellular cAMP accumulation (53). The inhibited CaMKII 
may induce PKA-mediated responses, increasing the levels of 
cAMP, which in turn could contribute to barrier stability. In fact, 
direct evidence has demonstrated the ability of Rcan1 to increase 
the phosphorylation of cAMP response element-binding protein 
through the negative regulation of the calcineurin signaling path-
way (54). Accordingly, Rcan1 overexpression decreases CaMKII 
levels in our EC system, supporting its role in the strengthening 
of the endothelial barrier.
FigUre 5 | Regulator of calcineurin 1 (Rcan1)-IRES-GFP inhibits COX2, CaMKII, and nitric oxide synthase 3 (NOS3) expression in human vein (HV)-endothelial cells 
(ECs). Figure shows the qPCR analysis of COX2, CaMKII, NOS3, MLC-kinase (MLCK), ROCK1, and RCAN1 mRNA of IRES-GFP and Rcan1-IRES-GFP HV-ECs 
treated or not with Hist 1 µM for 60 min. Values represent amounts of mRNA normalized to the endogenous gene. Unpaired t-test analysis was applied to untreated 
or histamine-treated cells. Data represent means ± SEM of duplicates determined by qPCR from indicated independent experiments: COX-2; ****P < 0.0001, 
Rcan1-IRES-GFP control (n = 13) vs IRES-GFP control (n = 12); #P = 0.0130, Rcan1-IRES-GFP histamine (n = 14) vs IRES-GFP histamine (n = 15); CaMKII; 
*P = 0.0454, Rcan1-IRES-GFP control (n = 9) vs IRES-GFP control (n = 8); Rcan1-IRES-GFP histamine (n = 6) vs IRES-GFP histamine (n = 6); NOS3; **P = 0.0044, 
Rcan1-IRES-GFP control (n = 6) vs IRES-GFP control (n = 6); Rcan1-IRES-GFP histamine (n = 5) vs IRES-GFP histamine (n = 5); RCAN1; *P = 0.0392, Rcan1-
IRES-GFP control (n = 10) vs IRES-GFP control (n = 10); Rcan1-IRES-GFP histamine (n = 11) vs IRES-GFP histamine (n = 9); MLCK; Rcan1-IRES-GFP control 
(n = 9) vs IRES-GFP control (n = 10); Rcan1-IRES-GFP histamine (n = 8) vs IRES-GFP histamine (n = 6); ROCK1; Rcan1-IRES-GFP control (n = 10) vs IRES-GFP 
control (n = 11); Rcan1-IRES-GFP histamine (n = 11) vs IRES-GFP histamine (n = 9).
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Molecular pathways based on disruption of cell–cell contacts 
and which are regulated by phosphorylation and de-phospho-
rylation of the myosin light chain are also relevant to this field 
of research (17, 55, 56). Although RhoA and ROCK have been 
recently recognized as key targets mediating histamine-induced 
vascular leakage and anaphylactic shock (14), our results do not 
reveal significant differences in MLCK/ROCK1 when Rcan1 
is overexpressed in HV-ECs. Nevertheless, the identification 
of COX2 as a downstream target of the CN/Rcan1 molecular 
pathway is a meaningful observation, and one which supports 
previous studies (57). COX-2 expression is induced by inflam-
matory stimuli and other mediators in the vascular wall, such 
as histamine, generating prostaglandin I2, and E2 production in 
HA-ECs (58). Proinflammatory phospholipid-derived media-
tors are critical modulators of vascular tone in physiological 
and pathological situations. COX-2 production induced by 
histamine has been reported in mast cells (19, 20). In addition 
to its products, prostaglandin D2, leukotrienes, thromboxane 
A2, and PAF are released rapidly in anaphylactic events (59, 60). 
In our studies, COX2 mRNA was substantially decreased upon 
histamine stimulation in Rcan1 overexpressed HV-ECs, sug-
gesting a major relevance of the axis histamine/Rcan1-4/COX2 
in anaphylaxis. In general, it can be speculated that both cell 
types (endothelial and mast cells) may contribute to prostanoid/
eicosanoid generation, which greatly render the vasoconstrictor/
vasodilator effects that occur in anaphylaxis. Our findings suggest 
that, through endothelial Rcan1 expression, histamine could also 
contribute to the regulation of important molecular pathways 
related to anaphylaxis, although further investigations need to be 
performed to confirm this.
Knowledge of the consequences of human Rcan1 overexpres-
sion is limited to evidence of genetic dysfunctions secondary to 
FigUre 6 | Regulator of calcineurin 1 (Rcan1)-deficient mice prevent histamine-induced vascular subcutaneous and systemic permeability but not systemic 
anaphylaxis. (a) Experimental mice models addressed in WT and Rcan1−/− mice. (B) Representative skin pictures of WT and Rcan1−/− mice s.c. injected with 
mediators at indicated concentrations. Evans blue extravasation was determined in four mice per genotype after subcutaneous injection of 20 µl of the indicated 
doses of histamine or PAF. Figure shows the amounts of Evans blue determined in skin dorsal punches as described in the Section “Materials and Methods.” Data 
represent means ± SEM. Unpaired t-tests were performed vs WT mice for each treatment and doses, *P = 0.0138 vs WT (5 ng/ml), *P = 0.0441 vs WT (50 ng/ml). 
(c) Graphic shows individual values of aorta and lung extravasation determined in seven (WT) and eight (Rcan1−/−) mice after 15 min of i.v. histamine injection 
together with Evans blue. Figure shows the amounts of Evans blue determined in tissues as described in the Section “Materials and Methods.” Data represent 
means ± SEM. Unpaired t-tests were performed vs WT mice. Aorta; *P = 0.0357, Lung; *P = 0.0319, Heart; ns = 0.1879 compared with Histamine WT mice.
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trisomy of chromosome 21 in patients with Down syndrome, 
who present defects of the immune system, though the preva-
lence of allergy is not high in these individuals (61). Previous 
studies using experimental anaphylaxis in Rcan1-deficient mice 
have found a role for Rcan1 in regulating Fc-εRI-mediated signal-
ing and mast-cell function (62). Rcan1−/− bone-marrow-derived 
mast cells show increased transcriptional activation of NF-κB 
and NFAT and calcineurin activity following stem-cell factor 
stimulation (63). On the other hand, Rcan1 seems to be required 
for the development of pulmonary eosinophilia in allergic 
inflammation in mice (64). Additionally, Rcan1 plays a protec-
tive role for respiratory infections and sepsis in experimental 
mice models (33, 65). Consistent with this, studies performed 
on Rcan1 transgenic mouse have found that Rcan1 gives rise to 
cancer protection by inhibiting the calcineurin pathway in the 
vascular endothelium (66). Moreover, as an endogenous inhibitor 
of calcineurin, Rcan1 has been involved as a negative regulator 
in inflammatory molecular pathways belonging to ECs (47). Our 
results in human ECs and an experimental mice model support 
the immunosuppressive function of Rcan1 for vascular perme-
ability and anaphylaxis.
We, here, show that endothelial Rcan1 maintains the integ-
rity of the endothelial barrier in HV-ECs. This effect is closely 
correlated with the cellular dilatory process that must occur in 
the resident cells once the primordial effect of endothelial bar-
rier breakdown has been induced by histamine. Extravasation 
or vascular permeability in micro-ECs may be best understood 
in terms of cellular contraction and dilatation, though cellular 
processes do not always correlate with physiology in vessels, and 
it is plausible that a similar process would occur in the context 
of anaphylaxis. Our results suggest that Rcan1 overexpression 
produces cell dilation, at least in HV-ECs, which correlates with 
the stabilization of the HMVEC-D barrier.
In summary, this work contributes to the knowledge of 
anaphylaxis, showing endothelial Rcan1 as an inducible 
molecule which is modulated in the endothelial compartment 
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upon contact with histamine through a calcineurin-sensitive 
pathway. Additionally, human functional assays and in  vivo 
experimental mice models suggest a role for endothelial Rcan1 
controlling vascular permeability, most likely to recover the 
loss of fluids, and pointing to Rcan1 as a plausible regulator 
of sensitivity to anaphylaxis in humans from the endothelial 
compartment.
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